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Abstract: Drug discovery encompasses processes ranging from target selection and validation to
the selection of a development candidate. While comprehensive drug discovery work flows are
implemented predominantly in the big pharma domain, early discovery focus in academia serves to
identify probe molecules that can serve as tools to study targets or pathways. Despite differences
in the ultimate goals of the private and academic sectors, the same basic principles define the best
practices in early discovery research. A successful early discovery program is built on strong target
definition and validation using a diverse set of biochemical and cell-based assays with functional
relevance to the biological system being studied. The chemicals identified as hits undergo extensive
scaffold optimization and are characterized for their target specificity and off-target effects in in vitro
and in animal models. While the active compounds from screening campaigns pass through highly
stringent chemical and Absorption, Distribution, Metabolism, and Excretion (ADME) filters for lead
identification, the probe discovery involves limited medicinal chemistry optimization. The goal of
probe discovery is identification of a compound with sub-µM activity and reasonable selectivity in
the context of the target being studied. The compounds identified from probe discovery can also
serve as starting scaffolds for lead optimization studies.
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1. Introduction
High-throughput screening (HTS) is an essential enabling technology for translational research
that can have endpoints of drug discovery or probe discovery [1]. The end point of drug discovery
is a complex process that leads to identification of a drug candidate that has potential for becoming
a marketed drug. Drug discovery is both a cost- and time-intensive process that requires integration of
expertise from various specialized teams and can take up to 15 years to bring a candidate molecule
to the market. Despite multi-million dollar investments in research and development (R&D) and in
implementing regulations, drug discovery and development is a very risky process for big pharma.
Risks arise from clinical trial failures due to lack of drug–target engagement, lack of correlation
between target and disease, and inadequate endpoint and patient selection. Other risks include patent
expirations and competition from generics, drug discontinuation due to long-term safety issues,
and poor efficacies across much larger genetically diverse populations. The high costs and risks and
long timelines of real world drug discovery are not compatible with the much shorter project milestones
and small research budgets of the academic world [2]. Notable exceptions to this generalization
include academic labs that pursue comprehensive early and pre-clinical drug discovery research
programs. The second endpoint of translational research, probe discovery, is a more viable alternative
in academic settings [2,3]. Probe discovery can be viewed as an intermediate short-term process of
compound identification, where the candidate molecule is used as a tool to dissect a biological process
or pathway of interest. The process of probe discovery is well suited to operating within limited
budgets, capturing short-term milestones defined by probe discovery publications and new grant
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submissions. Probe discovery also accommodates the vast array of targets and biological systems that
academics pursue regardless of commercial return on investment value.
2. Target Identification and Validation
Regardless of whether the goal of translational research is drug or probe discovery, both
endpoints require the identification of a target or a pathway via basic academic or clinical research.
Studies on the molecular mechanism of disease unravel targets that are relevant to disease
development and progression [4]. The targets range from proteins, mutations, or polymorphisms in
the coding or non-coding regions of the genome or transcriptional or post-translational regulatory
processes. At one end of the target spectrum, defining the role of target is relatively clearer in
simple mono-factorial diseases, which are characterized by one causative allele, and modulating
that single gene or factor theoretically increases the probability of targeting the disease effectively.
At the other end of the target spectrum, defining a target in complex multifactorial diseases is extremely
challenging. Complex diseases, including cancer, neurodegenerative disorders, and Type 2 diabetes,
are all heterogeneous and have variable phenotypes from risk factors that are a function of genetics,
age, gender, and diet or lifestyle choices. The challenges in identifying a unique target underlying
complex diseases arise from cellular cross-talks between signaling pathways and interaction networks
that result in functional redundancies and other compensatory mechanisms. As the industry strives to
constantly improve its capabilities and predictive powers in drug discovery to produce safer and more
efficacious drugs, it has become very clear that target information appears to fall short in many cases
in late-stage drug discovery. The importance of acquiring more comprehensive information on targets
of interest cannot be understated.
A target is deemed druggable when it is amenable to modulation either through genetic and/or
chemical experimentation. Modulation of the target should elicit a measurable and quantifiable
response, which in turn establishes a strong, unequivocal relationship between the target and
disease development or progression. The field of target identification mechanisms has been reviewed
extensively [5]. In short, the functional significance of a target in disease or pathogenesis can be
measured through the genetic manipulation of cells or animal model organisms using clustered
regularly interspaced short palindromic repeats (CRISPR-Cas9), transcription activator-like effector
nucleases (TALENs) and zinc-finger nucleases (ZFNs), RNA interference or microRNAs. Chemical
validation of the target can be performed using known compounds or available antibodies.
The probability of identifying a molecule that has high potential of engaging a target effectively
requires strong target validation data and helps in overall risk assessment [6]. The success of designing
relevant assay systems requires characterizing the target in both normal and pathogenic states:
sequence and structure, functional or structural redundancy, characterization of spliced isoforms,
posttranslational modifications, subcellular distribution, and mRNA and protein expression levels
across tissues, their half-lives, and regulation. Target deconvolution can also be attempted using mass
spectrometry following thermal protein stabilization (CETSA) [7] or affinity enrichment techniques in
the presence or absence of a drug, followed by genetic validation.
Target identification in recent years can also be supported from extraction and integration of
relevant information available from different datasets [8]. Extensive research and clinical observations
over the years have made available large volume “omics” datasets, which may prove critical in
target and drug discovery. Correlative integrations across omics databases are presumed to facilitate
the building of more comprehensive models of targets in disease. The high-throughput genomics,
transcriptomics, epigenomics, proteomics, and metabolomics can help establish strong gene/protein
variant associations and can aid in biomarker discovery. Ultimately, models emerging from strong
correlative datasets may help identify correct patient populations and define relevant clinical endpoints
for the diagnostics, prevention, or treatment of diseases.
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3. Assay Development
Probe or drug discovery requires development of a primary screening assay that faithfully
interrogates the target or pathway being studied. In addition to the primary assay, the screening
workflows also require secondary assays for hit characterization [9]. The assays can be developed using
biochemical or cell-based platforms. Biochemical assays are targeted assays that have well-defined
reaction components that are incubated with purified compounds to find inhibitors or activators.
Biochemical assays include enzymatic assays (direct or coupled) run as end-point or kinetic assays,
protein–protein or protein–DNA or protein–RNA interactions, or direct compound binding assays.
Cell-based assays range from being black box assays based on generic phenotypic read outs like
cytotoxicity or can be relatively more targeted, as in biomarker-based screens. Cell-based reporter
gene assays are built up on target sequences fused to reporters such as luciferase, β-galactosidase,
and fluorescent proteins. Phenotypic assays measure phenotypic or biochemical changes in cell lines,
primary cells, or zebrafish, Caenorhabditis elegans model organisms. Unlike the biochemical assay
readout, defining the mechanism of action of a compound identified through whole cell assays is
more complex. Cell-based assays are considered more mechanism-based if the screening readout is
a direct measure of target engagement, as in in-cell Western assays, split-protein complementation
(biomolecular luciferase or two hybrid assay systems), or using labeled substrates or indicators of
cellular enzymatic or translocation screens. The cell-based assays developed for high content imaging
are highly informative and can simultaneously provide information on cell morphology, integrity of
nucleus, cytoplasm or membranes in addition to other targeted processes being measured, e.g., changes
in intracellular localization or accumulation of lipid vesicles in algae. The relevance of the type of cells
used for developing a primary screen or secondary assays is critical for identification of a specific
probe/drug. The screens involving stem cells, patient-derived cells [10], and three-dimensional
spheroids formed from single cell lines or formed by mixing various organ-specific or tissue-specific
cell types has greatly expanded the capabilities of finding more relevant and translatable hits in cancer
and hepatocyte injury mechanisms. Many biochemical assays as well as cell-based reporter systems
usually contain smaller truncated functional domains of regulatory elements, proteins/enzymes for
convenience of purification or for improvement in signal windows. Compounds active against such
truncated targets may also need to be tested against full-length proteins or under more physiologically
relevant conditions.
In addition to the primary assay, probe and drug discovery work flows require setting
up additional assays that will be very useful downstream to characterize the compounds for
reconfirmation of activity as well as for defining selectivity and specificity [11]. The orthogonal
assays confirm the activity of compounds identified from the primary screen, while secondary assays
that target other known related members of a protein family or other relevant proteins will help define
compound selectivity. The orthogonal assays serve to confirm the activity of primary screening hits
against the target and eliminate compounds that interfere non-specifically with the primary assay
components or detection methodologies. For instance, while the luminescence-based Alpha screen
assay can be used to screen for compounds that inhibit protein–protein interactions, an assay based on
Homogeneous Time Resolved Fluorescence (HTRF) serves as an orthogonal assay to characterize the
interactions using fluorescence-based technology. Whenever possible, it is good practice to include both
biochemical and cell-based assays for the target or signaling pathway being investigated. The hits from
biochemical assays should be tested for their permeability across cell membranes and their ability to
modulate the target inside the cells. Likewise, the compounds identified from cell-based assays should
be tested for their ability to bind to the target of interest using biochemical or biophysical assay read
outs. While a compound that shows high potency in a biochemical screen but not in cell-based assay
and vice versa can still be pursued as there is always a chance that medicinal chemistry optimization
can help modify the physicochemical properties of the hit and make it more useful. In general,
compound screening work flows designed to include biochemical, biophysical, and cell-based assays
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provide better insight into the quality of hits and provide support for data-driven hit selection for
downstream processes.
4. Assay Optimization
For any system under consideration, it is the biology and practicality that dictates the type of
assay selected for high throughput screening. The assays developed for high throughput screening
are preferably homogeneous, involving up to two steps for their execution. Heterogeneous formats
requiring multiple additions and removal of reagents add to variability in signals when large number
of assay plates are processed. The assays should be scalable and able to be miniaturized from
96-well formats to 384–1536 high-density well microplate formats with no significant loss of response.
The assays for screening should be highly reproducible and robust. The same signal windows between
low and high counts from plate to plate and from day to day must be exhibited in positive and negative
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overexpressing proteins on  cell metabolism, growth kinetics,  and gene  expression. The  cell  lines 
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Figure 1. Representative assay optimization parameters. (A) Scatterplot of signal separation between
the high (RNA + protein) and low (RNA alone) polarization values, giving an acceptable band
separation and average Z’ values of 0.8. (B) Plots showing signal consistency in 3-day, 3 plate assay
and mid-point percent activity from inter- and intraday assays. The well numbers are shown on x-axis
of the plots. (C) Effect of passage number of chemical inducer of dimerization (CID)-dependent bone
marrow cells (BMC) on γ-globin promoter driven (GGP)-luciferase induction in the cell-based reporter
assay system.
The availability of large amounts of purified proteins, labeled peptides or nucleic acids, affinity of
interactions, the stability of reagents over time are some of the factors impacting biochemical assay set
ups. Cell-based assays require an understanding of the impact of passage number on assay readout
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(Figure 1C) and on cell physiology as well as the impact of expressing reporters or overexpressing
proteins on cell metabolism, growth kinetics, and gene expression. The cell lines being used should be
authenticated via short tandem repeat (STR) PCR analysis and be routinely screened for mycoplasma.
The assays are developed using any of the available platforms including fluorescence (fluorescence
intensity, polarization, Förster resonance energy transfer (FRET), and Time-resolved fluorescence
energy transfer (TR-FRET)), absorbance, luminescence, Bioluminescence resonance energy transfer
(BRET), Alphascreen technology, and label-free assay systems. For any new assay, a plate uniformity
and signal variability test is performed using conditions that generate a Min, Mid, or Max signal
values for any of the platform technologies. The signal reproducibility and signal separation between
the conditions generating high, medium, or low signals are tested by independently setting up three
plates per day over a period of three days. The “Max” signal measures the high read outs from
reactions or cells containing agonists or DMSO vehicle. The “Min” signal is the basal signal read from
a biochemical reaction that lacks an enzyme, or has a low concentration of agonist, or reactions with
high concentration of an inhibitor, all of which can reduce- the signal-output to > 80% of the untreated
response. The data is used to evaluate patterns of drifts and edge effects across rows and columns of
each plate. The inter- and intra-day tests measure shifts, if any, in the Mid signal, normalized to Max
and Min signals, signal windows, and a coefficient of variability (CV) (Figure 1B). An acceptable assay
shows SW > 2, CVMax and CVmin < 20%, and a normalized midpoint signal shift of <2. The distribution
of Max and Min signals or of high and low controls are also used to calculate a statistical screening
window factor called the Z factor. The Z’ factor is based on means and standard deviations of controls
(Z’ = 1 − (3SDhigh control + 3SDlow control)/|Meanhigh control − Meanlow control|. During screening, the
quality assessment on screen samples is used to calculate the Z factor, which is based on means and SD
of sample and negative controls (Z = 1 − (3SDsmaple + 3SDlow control)/|Meansample − Meanlow control|.
While the majority of biochemical and cell-based screens yield acceptable Z’ scores, the screening
positives in RNA interference-based screens are more noisy and can generate moderate to weak
effects, yielding a lower signal to noise windows and failing Z’ scores. Other statistical criterion has
been published (Strictly Standardized Mean Difference (SSMD), Receiver Operating Characteristic
curve (ROC) curves, Mean + standard deviation threshold (k), etc.) for defining quality standards of
RNAi screens [13,14]. More detailed discussion on practical aspects of establishing statistical criterion
measurements that certify the readiness of an assay for screening large compound collections can
be obtained from the NCBI [12]. The siRNA-based screening optimization is discussed in detail
in references [13,14]. The assays are transferred from bench top to automated robotic systems for
compound and liquid dispensing operations. The automation systems range from pin-tool tips to
acoustic transfer capabilities, the availability of which depends largely upon the academic facility
budgets and their optimal workflows.
5. Compound Screening Process
Once the assay meets the established statistical acceptance criterion for screening (e.g., signal
windows, coefficient of variability, reproducibility, Z’ factor, uniformity, etc.), the assay is first used
for screening a small training set of compounds (~2000–10,000), to verify that the assay is performing
acceptably. The test compound collections can vary with the screening facility or can be dictated by the
target class. The validation or test library can comprise a collection of small molecules representative
of scaffolds present in much larger compound sets, may include a collection of known bioactives that
include compounds with at least one known molecular target, and may include kinase or phosphatase
inhibitors or inhibitors of a cell cycle, proteasomes, etc. The data from the validation screening is
evaluated for various parameters like the Z’ scores, signal uniformity, hit rates, frequency of false
positives, and assay interference compounds.
Once the assay passes all validation screening parameters, larger compound collections are
screened at one or more concentrations. The primary screening can be performed at a single
concentration or can be performed at 6–8 concentrations in quantitative HTS format (qHTS) (Figure 2).
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The qHTS, though more cost- and time-intensive, helps in generating dose–response curves for
each of the compounds tested. The qHTS format also minimizes the selection of false positive hits.
Combination screening is yet another mode of screening in which the synergistic combination of
compounds is identified by combining either single or multiple concentrations of compound or drug
of interest with other drugs or bioactives or diversity scaffolds from focused libraries. Combination
screening can also be performed for drug repurposing projects where a clinical standard of care
is used to screen other US Food and Drug Administration (FDA)-approved drug collections to
identify more potent synergistic combinations of drugs for new indications or for improving efficacy
of existing standard of care. New combinations may help identify two or more drugs that target
multifactorial disorders and improve the quality of care. In addition to the wet bench HTS campaigns,
virtual screening can also be performed to select primary hits. The confidence of hit identification via
virtual screens increases if the screening model is supported by X-ray crystal structures of binding
domains or co-crystal models with ligands. The challenges of defining a theoretical low energy model
in the absence of crystal structure information makes true positive identification from virtual screening
more challenging. In contrast to HTS, which is dependent on actual available compound libraries,
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Figure 2. Steps in early rug/probe discovery. Translational programs require stringent target identification
and validation information. Druggable targets are screened either virtually using virtual compound
structure databases or via biochemical or cell-based assay screening of available chemical or peptide
libraries. High throughput Screening (HTS) can be performed with single purified compounds at one or
more concentrations (qHTS). Combination screens are performed to identify synergistic combinations of
bioactives. Drug repurposing screens identify new targets for FDA-approved drugs, while multi-target
drug discovery (MTDD) approaches identify compounds with activity against two unrelated targets.
Minimal chemical scaffolds can show binding promiscuity and can modulate several targets that
share functional domains and binding sites across target families. The multiple target modulation
by a drug or polyph rmacology is exploited in screens for drug repositioning that help in the
identification of new indications for marketed drugs. Identification of new activity for a market d
drug via experimental and in silico-based approaches fits well within the scope of academic discovery
projects, as the safety, toxicity profiles, formulations, and pharmacology of marketed drugs are already
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established. A combination of two or more FDA-approved drugs against a target may improve
outcomes especially if the combinations target the crosstalk between pathways that are activated
or repressed in disease settings. Another form of multi-target drug discovery (MTDD) screening
involves identification of single compounds with activity against two or more targets that reside in the
same tissue or cell compartment. In such screens, the hit compounds identified from the first screen
against a target are used against the second target of interest to identify scaffolds with activity against
both targets. Both experimental as well as virtual in silico approaches can be used to design screens
to identify compounds that are active against multiple targets of interest. Several rationally based
designs, computationally based docking, and virtual screening approaches are available for identifying
drugs with multiple functions. The prediction of interactions between a chemical compound and
other potential biological targets require a mining of “omics” datasets, molecular docking using
X-ray crystal structures or models, ligand-based quantitative structure–activity relationship (QSAR)
similarity prediction of two- or three-dimensional fingerprints of small molecules, and binding pocket
subcavities that have been shown to accommodate known drugs across proteins that lack sequence
similarity [15]. Polypharmacology-based screens can help in the selection of molecules that have higher
efficacy and lower toxicity.
6. Screening Libraries
The assay interrogating a target is used to screen collections of chemicals or nucleic acids
or peptides. The chemical collections or libraries include fragments ((<300 Da), small organic
molecules (300–500 Da) and macrocycles or larger structures of high molecular sizes. Libraries of
small organic molecules are used most extensively in small molecule high throughput screening
campaigns. The chemical libraries are either available commercially through vendors or are chemical
collections synthesized by academic scientists. The libraries may be available as diversity scaffolds
that generally follow Lipinski’s Rule of Five (Ro5) concept for bioavailability. The Ro5 criterion
leads to the selection of molecules that are <500 Da, have <5 H bond donors (N–H & O–H bonds),
have <10 H bond acceptors (N + O), and have a octanol–water partition coefficient logP <5 [16].
The compound collections are routinely screened with filters to eliminate chemical liabilities or
synthetically challenging scaffolds. The filters can remove scaffolds with known reactivities, detergents,
denaturing agents, oxidizing/reducing agents, etc. or pan assay interference compounds (PAINS),
which are associated with promiscuous activity or possess assay interference attributes [17]. Several
filters such as Rapid elimination of Swill (REOS), Lilly Rules [18] and PAINS filters are currently
available, and, when used in parallel, the filters collectively can flag from 5 to 60% of the vendor library
compounds (personal communication). Scaffold collections are also selected via in silico design based
on known bioactives to form focused libraries against popular targets like ion channels, kinases, Hsp90,
proteases, anti-fungal, or anti-infective properties or selected in silico for having properties to cross the
blood–brain barrier. Several reports indicate that the vast majority of approved drugs belong to small
classes of organic molecules and that half of all bioactivity is associated with less than 5% of the known
chemical scaffolds. A much larger chemical space is represented by fragment collections, which follow
the rule of three (Ro3) criterion [19,20]. Fragments are selected based on a molecular weight <300,
having ≤3 H bond acceptors, having ≤3 H bond donors, and having a clogP <3. Fragment-based
screening is generally performed using NMR-based or Biacore- or X-ray crystallography driven
screening platforms. FDA-approved drugs as well as known bioactives comprise yet another type
of screening sets that can be utilized for drug repurposing screens [21]. The FDA-approved drugs
provide an opportunity to fast track the discovery process as the pre-clinical and clinical safety data is
already available [22]. The partial coverage of chemical space has also supported expanding screening
to purified natural products and into exploring compounds from rich biodiversity in terrestrial and
marine organisms. The problems of purification and scale-up production of active scaffolds from
natural extracts limit access to large natural product collections that are available for screening.
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In addition to the chemical libraries, genomic screening uses collections of siRNAs [23],
microRNAs [24], or CRISPR libraries [25]. Genomic screens provide valuable target and mechanistic
information but can often result in complex datasets. Phenotypic assays are used to screen biologics,
which have proven to be highly effective therapeutic agents, and the path to their discovery is distinct
from that followed for small molecule development. The biologics include recombinant protein-based
therapies such as monoclonal antibodies, growth factors, hormones, vaccines, and anticoagulants that
are produced in bacteria, yeast, and mammalian cells [26]. Peptide-based drug discovery [27] is yet
another major area of screening but has its own challenges in terms of their stability and availability.
In addition to the above agents, stem cells by themselves hold great promise as novel therapeutic agents
but require precisely defining human cell lineages, identifying markers, niche-dependent potency and
process-controlling proliferation, differentiation, and functional specialization. Gene expression-based
RT-PCR (reverse transcription-polymerase chain reaction) screens are also used to identify compounds
that can help maintain the self-renewal potential of stem cells. Such screens help in identifying hits
that directly or in combination with genetic factors, can support generation of induced pluripotent-
and lineage-specific stem cells from somatic cell types.
7. Actives: Hits to Leads
“Actives” are compounds that show activity in the primary assay. The single concentration
primary screens are followed by activity reconfirmation in up to a ten-concentration dose–response.
Since the primary hit rates can range from 0.1% (for some biochemical screens) to as high as 4% for
some cell-based screens, it is useful to include a selectivity and/or cytotoxicity assay at this stage
of hit identification. The dose–response curves are analyzed for their quality (Hill slopes, potency,
and efficacy). At this stage, the reconfirmed hits are also evaluated for their promiscuous activities
across other known screening datasets. These include internal HTS databases as well as large data
collections in the PubChem database [28]. Compounds with activities against other targets or known
assay interference characteristics are culled or deprioritized and a relatively selective set of hits
from the screen are subjected to cheminformatics analysis [29–31]. Cheminformatics analysis utilizes
multiple approaches based on Tanimoto coefficients, daylight substructural fingerprints, or modified
Jarvis–Patrick non-hierarchical cluster analysis [32] to group the hits into several structure–activity
clusters. The cheminformatics datasets are analyzed by medicinal chemists for structural features for
easy chemical manipulation, and a few representative compounds from each cluster are re-purchased
as fresh powders from vendor catalogs or synthesized in-house. Repurchasing new powders ensures
that the observed activity corresponds to a unique intact scaffold and is not due to some impurity
or degradation or transformed scaffold in DMSO stocks, which, in HTS labs, undergo several
freeze–thaw cycles over time. The purity of repurchased/synthesized compounds is established
by liquid chromatography–mass spectrometry (LC-MS) analysis. The activity from the fresh powders
that are >95% pure is again tested in the primary screening assay as well as other follow-up secondary
assays (selectivity screens, cytotoxicity studies, activity in a physiologically relevant assay, distinct
from the primary assay). A proof of concept data for early discovery is generated, and, at this stage,
analoging by catalog or by synthesis is initiated, or grants are submitted for acquiring funding for
further development of the scaffolds.
To ensure that the hits are not false positives that interfere with assay detection methodologies,
the hits are validated using orthogonal assays based on detection technology distinct from the primary
screening assay. At this stage, a wide range of low to medium throughput assays are employed to
further characterize the hits. Some of these assays include RT-PCR, Western blot analysis, cytotoxicity
assays to establish mechanism driven cell lethality, target selectivity assays for screening across a panel
of orthologous targets or for infectious diseases, and a panel of Gram-negative or Gram-positive
bacteria. Mechanistic studies are greatly encouraged to define mode of action.
The molecular scaffolds from iterative medicinal chemistry optimization result in the identification
of “probe” molecules, which show high potency (<100 nM for biochemical screen, <1–10 uM for
High-Throughput 2018, 7, 4 9 of 14
cell-based assays), high efficacy (maximal effects in physiologically relevant systems), and good
selectivity (ranging from >10 fold difference to >100 fold, depending upon the biological system) [33].
High quality probes are also expected to exhibit good aqueous solubility and membrane permeability
properties [34].
A simple screening tier is shown in Figure 3. The overall goal of the project was the identification
of small molecules that reactivate expression of γ-globin (HbF, fetal hemoglobin), which has therapeutic
significance in the treatment of sickle cell anemia [35]. The assay utilized immortalized multipotential
cells derived from the bone marrow of transgenic mice, stably expressing a dual luciferase construct,
with firefly luciferase under fetal globin promoter and Renilla luciferase under the control of the
β-globin promoter. The screening parameters including cell passage numbers were optimized in
384-well format, and the cell lines were characterized for their ability to respond to at least 10 known
inducers of fetal globin-like hydroxyurea, sodium butyrate, valproic acid, valeric acid, etc. The assay
was used to screen 120,000 compounds from the University of Kansas HTS compound collection and
232 compounds were found to upregulate firefly luciferase after 24 h of incubation. The actives
were clustered into 12 structural groups and fresh compounds were repurchased from various
vendors. Three cell-based secondary assays were performed using the freshly available compounds
for their ability to modulate firefly luciferase, Renilla luciferase, and general cytotoxicity in bone
marrow progenitor cells. The activity of compounds was also tested against purified luciferase in
an optimized biochemical assay. Profiling of the compounds revealed that at least 50% of the screen
actives selectively upregulated firefly luciferase but did not upregulate β-globin promoter-driven
Renilla luciferase activity. The compounds that selectively upregulated firefly luciferase activity also
did not inhibit purified luciferase enzyme activity and were not toxic to bone marrow progenitor cells.
The concentration–response curves show activity of two such compounds identified in a primary
screen: K001 and K002 upregulated firefly luciferase up to 10-fold and did not upregulate Renilla
luciferase activity. The most potent and selective compounds were tested for their effects on fetal
globin RNA and protein levels using the primary human erythroid cultures generated in vitro from
adult CD34+ stem cells. The erythroid stem cells were treated with compounds for 48 h and harvested
for gene expression and fluorescence-activated cell sorting(FACS) analysis. The test compounds were
found to induce a 2.8–2.9-fold increase in the ratios of fetal gamma to β-globin RNA level compared
with 1.8-fold increases with known inducer sodium butyrate. FACs analysis showed a 2–5-fold increase
in fetal globin positive cells. These results indicate that the actives identified in the high throughput
screening assay using a reporter assay were also functional as HbF inducers under a physiologically
relevant human primary erythroid cells.
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8. Hit to Lead Optimization
Hit to lead optimization programs are executed to identify hit classes that are chemically tractable
and serve as good starting points for developing quantitative structure activity relationships [32].
A more involved chemistry and absorption, distribution, metabolism and excretion (ADME) program
is initiated for hit to lead optimization. Chemical optimization of generally from 2 to 10 scaffolds
series for drug discovery are initiated to improve potency and efficacy and selectivity of compounds.
The compounds acquired or synthesized through medicinal chemistry efforts are tested iteratively
in a few selective assays. Selectivity screens are often expanded to include related target class panels
or with unrelated targets. A simultaneous evaluation of in silico analysis of compound solubility,
permeability, and toxicity profiles is performed. Molecular modeling and crystallization docking
programs can be run in parallel for rational and informed compound analog design. Over the
last few years, cellular thermal shift assays (CETSAs) have been a highly recommended choice for
defining drug–protein interactions in cells in medium to high throughput formats [7,36]. In addition to
their various applications, CETSAs are a powerful tool used not only to confirm the binding of the
compound to target of interest but can also be used to define off-targets via mass-spectrometric
analysis of compound-stabilized proteins in the cell. Using various approaches, the hit to lead
optimization program results in the identification of new analogs with improved potency, high efficacy,
reduced off-target activity, and >100-fold windows between non-specific cytotoxicity and target
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activity. Physico-chemical properties include testing analogs for permeability and absorption through
Caco-2 cells, metabolic stability in rat/mouse and human microsomes, cytochrome P450 inhibition,
human ether-a-go-go-related gene (hERG) channel inhibition, and plasma protein binding. Parallel
improvement in physico-chemical and metabolism-related properties greatly improve the prediction of
outcomes in subsequent pharmacokinetics and pharmacodynamics models. Lead identification results
from developing highly optimized scaffold molecules with good drug-like properties, high efficacy
and potency and with acceptable selectivity. The final lead scaffolds bear very low semblance to the
original hit identified through screening chemical libraries. Toxicology studies in at least two animal
models species as well as conformation to regulatory studies are performed at this stage. A thorough
understanding of target biology enables a clearer understanding of the mechanism of action of the lead
compounds. Target- and off-target binding studies help- in defining a mechanism of action of hits and
also in the identification of other related or unrelated targets and signalling pathways. Information
on tissue distribution of the hit molecule is critical for quantifying compound exposure at the site
of action, whereas on-target occupancy helps to in defining drug efficacy and engagement time [37].
Assays and disease models that establish correlations between the functional effects of molecule–target
interaction and a quantifiable and physiologically relevant phenotype in disease models are critical for
validating role of targets and chemical molecules in disease.
9. Overall Impact of Academic Early Discovery Programs
Early discovery programs in academia have contributed significantly to both the fundamental
processes and screening resources in early probe/drug discovery. Academic drug discovery programs
started evolving at a time when the patents in big pharma settings were nearing expirations and
the industry started engaging in more collaborative and open innovation discovery paradigms [38].
The new industry mind-set in combination with the enhanced translational focus of National Institutes
of Health (NIH) led to the emergence of screening centers. The NIH-funded Molecular Libraries
Probe Production Centers Network (MLPCN) helped set up comprehensive screening centers and
specialized chemistry centers, which triggered academic screening programs. The pharma-dominated
drug discovery endeavors were guided largely by Return on Investment (ROI)-driven business
decisions that supported low risk projects affecting large patient populations, often leading to the
discovery of “me-too” drugs. Academic drug discovery stepped in to fill the gaps in target discovery
and in expanding the chemical space. Academic early discovery programs have helped identify
targets for unmet medical needs, in almost all areas of human diseases, including cancer and many
metabolic, neurological, and infectious diseases. The small molecule screening decks expanded due
to novel compounds and novel synthesis protocols emerging from academic synthetic chemistry
research [39–41], or from the NIH-funded Chemical Methodologies and Library Development (CMLD)
programs [42–44]. Several new methodologies and approaches have been reported in literature
for hit evaluation [6,18,29,45–48], tapping dark matter as starting leads [49], and shifting focus
to covalent binders [50]. The NIH-MLPCSN programs have provided excellent guidelines to the
academic community for adapting their target ideas into successful HTS assays. The screening grants
based on the principal investigator’s biology have helped expand the scope of academic research,
have supported screening and hit optimization projects of academic HTS and medicinal chemistry
laboratories, and have supported the research infrastructure costs of universities and departments.
10. Summary
Chemical probes generated through academic programs can provide valuable information on
target biology and translatability. The NIH Molecular Libraries Program contributed significantly
towards probe discovery and developed 375 probes against a large number of targets [42].
The academic drug discovery consortium [51] (ADCC; [52]) lists 149 drug discovery centers across
the world. While some of the screening centers focus on specific diseases or capabilities, a vast
majority of the screening facilities work on a wide range of targets and diseases [53]. The screening
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centers differ in the size of screening resources (compound collections, automation equipment,
platform detection technologies and capabilities) as well as in the extent of a university’s drug
discovery infrastructure support. The extent to which an academic discovery project is taken along
the course of mid- to late-stage discovery depends largely on resources and an interest in establishing
multidisciplinary collaborations as well as on obtaining funds for medicinal chemistry optimization,
ADME, pharmacokinetics and pharmacodynamics, formulations and toxicology are bottlenecks for
majority of the academic programs. The most productive collaborations arise when the high quality
probes developed in academic early discovery programs move further into the late-stage discovery
workflows in pharma settings. Around 24% of FDA-approved drugs between 1998 and 2007 were
reported to have emerged from transfer of scientifically innovative university patents to biotechnology
and pharmaceutical companies [54]. Academic probe discovery programs have not only expanded
the scope of academic basic research projects but have also brought in innovative approaches into
traditional drug discovery processes.
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